August 29, 2016 10:47 PM ET

Biotechnology

Company Overview of Roche Glycart AG

Executive Profile

Laus Breiner Ph.D.

AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 1 different industries.

See Board Relationships
----

Background

Mr. Laus Breiner, Ph.D. serves as Investment Manager of Global Life Science Ventures. Mr. Breiner serves as a Director of Roche Glycart AG.

Corporate Headquarters

Wagistrasse 18
Schlieren, Zurich 8952

Switzerland

Phone: 41 44 755 61 61
Fax: 41 44 755 61 60

Board Members Memberships

Director

Education

There is no Education data available.

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Roche Glycart AG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.